SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Bloomberg News [Mulier, Thomas / Kresge, Naomi]. (12/22/17). "Press Release: Roche to Buy U.S. Cancer-Drug Maker Ignyta for $1.7 Billion. Deal Comes Five Weeks after Bayer Licenses Similar Drug".

Organisations Organisation Roche (Group)
  Organisation 2 Ignyta Inc. (Nasdaq: RXDX)
  Group Roche (Group)
Products Product entrectinib
  Product 2 larotrectinib (LOXO-101)
Index terms Index term Ignyta–Roche: investment, 201712– cash tender offer $1.7b for all outstanding shares at $27/share
  Index term 2 Bayer–Loxo Oncology: TRK inhibitors, 201711– ww collab $400m upfront + $650m milestones developm of larotectinib + LOXO-195

Record changed: 2017-12-28


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Roche (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSG] – The Business Web Portal 600x80px

» top